[1] [1] Fan Y, Li Y, Chu Y, et al. Toll-like receptors recognize intestinal microbes in liver cirrhosis[J]. Front Immunol, 2021, 12: 608498.

[2] [2] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.

[3] [3] Fallowfield JA, Jimenez-Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis[J]. Expert Emerg Drugs, 2021, 26(2): 149-163.

[4] [4] Zhang YW, Wei FX, Wei ZG, et al. Elective splenectomy combined with modified Hassab's or Sugiura procedure for portal hypertension in decompensated cirrhosis[J]. Can J Gastroenterol Hepatol, 2019, 2019: 1208614.

[6] [6] Korkmaz FT, Shenoy AT, Symer EM, et al. Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury[J]. JCI Insight, 2022, 7(23): e149955.

[7] [7] Musso G, Cassader M, De Michieli F, et al. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis[J]. Am J Clin Nutr, 2011, 94(4): 1033-1042.

[8] [8] Ramachandran J, Sajith KG, Priya S, et al, Serum cholinesterase is an excellent biomarker of liver cirrhosis[J]. Trop Gastroenterol, 2014, 35(1): 15-20.

[17] [17] Barreto J, Karathanasis SK, Remaley A, et al. Role of LOX-1 (lectin-like oxidized low-density lipoprotein receptor 1) as a cardiovascular risk predictor: mechanistic insight and potential clinical use[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1): 153-166.